Latest news with #immunotherapy
Globe and Mail
12 hours ago
- Business
- Globe and Mail
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
SAN DIEGO and CALGARY, AB, July 22, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a leading clinical-stage company specializing in immunotherapy for oncology, received a formal letter (the "Compliance Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated July 22, 2025 informing the Company that it has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). The Company is now in compliance with all Nasdaq listing standards, and its common shares will continue to trade on the Nasdaq Capital Market under the ticker "ONCY."
Yahoo
13 hours ago
- Business
- Yahoo
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
SAN DIEGO and CALGARY, AB, July 22, 2025 /CNW/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a leading clinical-stage company specializing in immunotherapy for oncology, received a formal letter (the "Compliance Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated July 22, 2025 informing the Company that it has regained compliance with the minimum bid price requirement under Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). The Company is now in compliance with all Nasdaq listing standards, and its common shares will continue to trade on the Nasdaq Capital Market under the ticker "ONCY." Oncolytics Biotech® Inc. Logo (PRNewsfoto/Oncolytics Biotech® Inc.) As previously announced, the Company was notified by Nasdaq on February 13, 2025, that the Company's common shares failed to maintain a minimum bid price of US$1.00 over the previous 30 consecutive business days as required by the Minimum Bid Price Requirement. According to the Compliance Notice, the Company regained compliance with the Minimum Bid Price Requirement because the closing bid price of the Company's common shares has been at or above $1.00 per share for 10 consecutive business days, from July 8, 2025, through July 21, 2025, and the matter is now closed. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype – turning "cold" tumors "hot" – through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: or follow the company on social media on LinkedIn and on X @oncolytics. Company Contact Jon Patton Director of IR & Communication jpatton@ Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 mmoyer@
Yahoo
16 hours ago
- Health
- Yahoo
New hay fever pill will retrain the immune system
A first-of-its kind hay fever pill is to be rolled out on the NHS. The immunotherapy drug aims to treat the root cause of symptoms by retraining the immune system to tolerate tree pollen over three years of daily use. Betula verrucosa, sold under the brand name Itulazax 12 SQ-Bet and made by ALK-Abello, is a tablet that contains birch pollen extract. It has been recommended by the National Institute for Health and Care Excellence (Nice) to be an option the NHS for around 27,000 people whose hay fever symptoms persist even after taking antihistamines or using nasal sprays. About 13 million people in the UK have hay fever during the spring and summer months, and about one in four sufferers are allergic to tree pollen. Severe tree pollen allergies can cause debilitating symptoms for some people during the spring and summer months, including fatigue, breathing difficulties, inflamed sinuses, itchy, watery eyes and changes in vision. Trials show the tablet can significantly reduce the symptoms of severe hay fever by changing how the body responds to allergens. Could benefit 27,000 people The immunotherapy works by gradually increasing the body's tolerance to tree pollen through controlled daily exposure to small amounts of pollen. Before being given the tablets, patients will require a skin prick or blood tests to confirm an allergy to birch tree pollen. Nice estimates that about 27,000 people in England are expected to benefit from the recommendation. Helen Knight, director of medicines evaluation at Nice, said: 'This treatment will help improve people's quality of life. 'Severe tree pollen allergies trap people indoors during beautiful weather and disrupt their work, education and family life. 'The daily tablet offers genuine long-term relief rather than just managing symptoms.' According to Allergy UK, birch pollen allergy is estimated to affect about a quarter of hay fever sufferers. Amena Warner, head of clinical services at Allergy UK, said: 'Many people don't realise how awful it is having an itchy, runny nose, sneezing episodes or itchy, irritated eyes in the pollen season. 'We frequently hear from people who avoid time outdoors, keep doors and windows shut, check pollen counts and try and minimise any exposure, which takes a significant toll on their physical and emotional wellbeing. 'Nice's recommendation is so important because it provides a genuine opportunity for people to manage the root cause of their pollen allergy, offering the chance to break free from this burden and enjoy a better quality of life.' Emil Stage Olsen, ALK-Abello's general manager for the UK and Ireland, added: 'We welcome this positive Nice recommendation, which is another meaningful advancement for the UK allergy community. 'Our focus is now on working closely with the NHS to ensure eligible patients can benefit from this first-in-class immunotherapy.' The NHS in England will provide the treatment within three months of Nice publishing its final guidance. Prof Meghana Pandit, co-medical director at NHS England, welcomed the announcement. She said: 'This innovative treatment, which will soon be rolled out on the NHS, enables patients to build up tolerance to birch tree pollen within their immune system, rather than just treating the symptoms – and we hope this will give many a new lease of life, allowing people to spend time enjoying being outside, without the discomfort allergies can bring.' Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more. Solve the daily Crossword
Bloomberg
19 hours ago
- Health
- Bloomberg
FDA Rejects Replimune's Skin Cancer Treatment, Shares Sink
US regulators rejected a skin cancer treatment from Replimune Group Inc. in another sign of the agency's new leadership taking a hard line on drug approvals. The US Food and Drug Administration denied the company's application to treat advanced melanoma with a combination of its immunotherapy and another cancer drug.
Yahoo
21 hours ago
- Health
- Yahoo
Man's deadly brain cancer tumor disappears after experimental drug trial
A man with the deadliest form of brain cancer has no signs of the disease after taking an experimental drug. Ben Trotman was 40 when he was diagnosed in 2022 with glioblastoma, the most aggressive cancerous brain tumor. Patients typically live an average of 15 months after diagnosis, and the five-year survival rate is just 6.9%. Trotman was referred to The National Hospital for Neurology and Neurosurgery at University College London Hospitals (UCLH), where he was treated by consultant UCLH medical oncologist Dr. Paul Mulholland, as detailed in a press release. Ancient 'Pharaoh's Curse' Fungus Shows Promise In Killing Cancer Cells As the only person enrolled in a trial that ultimately closed due to lack of patients, Trotman received a medication called ipilimumab, a targeted immunotherapy treatment. Ipilimumab is an antibody that binds to a protein on immune cells (T cells). It keeps cancer cells from suppressing the immune system so it can then attack and kill the cancer, according to the National Cancer Institute. Read On The Fox News App Trotman also received radiation and chemotherapy. More than two years later, his quarterly scans show no signs of cancer. "It is very unusual to have a clear scan with glioblastoma, especially when he didn't have the follow-up surgery that had been planned to remove all of the tumor that was initially visible on scans," his oncologist, Mulholland, said in the release. "We hope that the immunotherapy and follow-up treatment Ben has had will hold his tumor at bay — and it has so far, which we are delighted to see." Two months after receiving the ipilimumab, Trotman married his wife, Emily. In April 2025, they welcomed their daughter, Mabel. "Getting this diagnosis was the most traumatic experience — we were grappling with the fact that Ben had gone from being apparently perfectly healthy to having months to live," Emily Trotman said in the release. "Had we not met Dr. Mulholland, that would have been it for us. We felt we had a lucky break in an otherwise devastating situation." Ben Trotman added, "We obviously don't know what the future holds, but having had the immunotherapy treatment and getting these encouraging scan results has given [us] a bit of hope." "We are focused on rebuilding the life we thought we had lost and enjoying being parents." Mulholland and his team have now opened another clinical trial for patients who have been newly diagnosed with glioblastoma. Click Here To Sign Up For Our Health Newsletter Sixteen patients will be recruited for the trial, which is sponsored by UCL. The treatment will be administered at the NIHR UCLH's Clinical Research Facility and the National Hospital for Neurology and Neurosurgery, according to the press release. The patients will receive ipilimumab before proceeding to standard treatments that may include surgery, radiotherapy and chemotherapy. "The crucial element of this trial is that patients will have their immune system boosted by the drug before they have any other treatment, when they are fit and well enough to tolerate the immunotherapy," Mulholland said in the release. The Win-Glio trial — nicknamed "Margaret's Trial" — is funded by the efforts of Dame Siobhain McDonagh, sister of Margaret McDonagh, a London woman who died of glioblastoma in 2023 and was treated by Mulholland. For more Health articles, visit Ben Trotman said he is "delighted" that the new trial is moving forward with the same immunotherapy drug he received. "It will give people newly diagnosed with glioblastoma some hope."Original article source: Man's deadly brain cancer tumor disappears after experimental drug trial
